

Correction: *First use of cenerimod, a selective S1P₁ receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study*

Hermann V, Batalov A, Smakotina S, et al. First use of cenerimod, a selective S1P₁ receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. *Lupus Science & Medicine* 2019;6:e000354. doi: 10.1136/lupus-2019-000354.

The authors want to alert the readers to the error identified in Supplementary file 7.

The original Supplementary file 7 included the number of patients (n) in the full analysis set for each cenerimod dosage. The revised file has been amended to show the correct n numbers, which is the number of patients included in the modified pharmacodynamics set (mPD set).



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

Lupus Sci Med 2020;7:e000354corr1. doi:10.1136/lupus-2019-000354corr1

